These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1160 related articles for article (PubMed ID: 23402224)

  • 1. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.
    Boyraz B; Sendur MA; Aksoy S; Babacan T; Roach EC; Kizilarslanoglu MC; Petekkaya I; Altundag K
    Curr Med Res Opin; 2013 Apr; 29(4):405-14. PubMed ID: 23402224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature.
    Martínez MT; Pérez-Fidalgo JA; Martín-Martorell P; Cejalvo JM; Pons V; Bermejo B; Martín M; Albanell J; Lluch A
    Crit Rev Oncol Hematol; 2016 Jan; 97():96-106. PubMed ID: 26318092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.
    Krop I; Winer EP
    Clin Cancer Res; 2014 Jan; 20(1):15-20. PubMed ID: 24135146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer.
    LoRusso PM; Weiss D; Guardino E; Girish S; Sliwkowski MX
    Clin Cancer Res; 2011 Oct; 17(20):6437-47. PubMed ID: 22003071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer.
    Lambert JM; Chari RV
    J Med Chem; 2014 Aug; 57(16):6949-64. PubMed ID: 24967516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer.
    Barginear MF; John V; Budman DR
    Mol Med; 2013 Jan; 18(1):1473-9. PubMed ID: 23196784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab emtansine for HER2-positive advanced breast cancer.
    Verma S; Miles D; Gianni L; Krop IE; Welslau M; Baselga J; Pegram M; Oh DY; Diéras V; Guardino E; Fang L; Lu MW; Olsen S; Blackwell K;
    N Engl J Med; 2012 Nov; 367(19):1783-91. PubMed ID: 23020162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
    Corrigan PA; Cicci TA; Auten JJ; Lowe DK
    Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
    Hurvitz SA; Dirix L; Kocsis J; Bianchi GV; Lu J; Vinholes J; Guardino E; Song C; Tong B; Ng V; Chu YW; Perez EA
    J Clin Oncol; 2013 Mar; 31(9):1157-63. PubMed ID: 23382472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.
    Van den Mooter T; Teuwen LA; Rutten A; Dirix L
    Expert Opin Biol Ther; 2015 May; 15(5):749-60. PubMed ID: 25865453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
    Baron JM; Boster BL; Barnett CM
    J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antibody-drug conjugates in oncology: from the concept to trastuzumab emtansine (T-DM1)].
    Gonçalves A; Trédan O; Villanueva C; Dumontet C
    Bull Cancer; 2012 Dec; 99(12):1183-91. PubMed ID: 23247898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
    Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
    Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer.
    Haddley K
    Drugs Today (Barc); 2013 Nov; 49(11):701-15. PubMed ID: 24308017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ado-trastuzumab emtansine for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer.
    Patel KC; Hageman K; Cooper MR
    Am J Health Syst Pharm; 2014 Apr; 71(7):537-48. PubMed ID: 24644113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System.
    Piwko C; Prady C; Yunger S; Pollex E; Moser A
    Clin Drug Investig; 2015 Aug; 35(8):487-93. PubMed ID: 26123628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
    Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
    BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
    Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
    J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer.
    Kashiwaba M; Ito Y; Takao S; Doihara H; Rai Y; Kanatani K; Takashima S; Masuda N
    Jpn J Clin Oncol; 2016 May; 46(5):407-14. PubMed ID: 26917603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.
    Yardley DA; Krop IE; LoRusso PM; Mayer M; Barnett B; Yoo B; Perez EA
    Cancer J; 2015; 21(5):357-64. PubMed ID: 26389758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.